Hyperparathyroidism secondary
Not recruitingStudy on the Effectiveness and Safety of PLS240 for Treating Secondary Hyperparathyroidism in Patients with End Stage Kidney Disease on Hemodialysis
Study on the Effectiveness and Safety of PLS240 for Treating Secondary Hyperparathyroidism in Patients with End Stage Kidney Disease on Hemodialysis
- Disease:Hyperparathyroidism secondary
- Substances:Upacicalcet Sodium Hydrate
Spain- Participants:18–64 years · 65+ years
- Substances:Upacicalcet Sodium Hydrate
- Sponsor:Pathalys Pharma Inc.











